Abstract
Adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) against CD19 glycoprotein has already shown long-lasting clinical remission in patients with some types of B-cell lymphomas and leukemias. However, in patients with chronic lymphoid leukemia, treatment response is restricted to about 20% of patients and there is no evidence of therapeutic efficacy in solid tum…